Neurofibromatosis type 1

Changed by Bruno Di Muzio, 18 Sep 2014

Updates to Article Attributes

Body was changed:

Neurofibromatosis type 1 (NF1) or von Recklinghausen disease is a multisystem neurocutaneous disorder and the most common phakomatosis 1. Additionally it is also one of the most common inherited CNS disorders, autosomal dominant disorders and inherited tumour syndromes. 

Epidemiology

Neurofibromatosis affects 1:2500-3000 individuals 3. In half of cases, the disease is inherited as an autosomal dominant condition. In the other 50% of cases the disease is due to a new mutation 6. There is variable expression but 100% penetrance by 5 years of age 6.

Clinical presentation

As is the case with many phakomatoses, NF1 results in a variety of abnormalities of variable severity. To make the clinical diagnosis you require two or more of following2:

In addition 30-60% of patients have learning disabilities.

Neoplasms

It should come as no surprise that a disease due to inactivation of a tumour suppressor gene (see below) is also associated with increased incidence of numerous tumours 1-6:

Pathology

The NF1 gene locus is on chromosome 17q11.2 and the gene product  is neurofibromin, acts as a tumour suppressor; inactivation of the gene thus predisposes to tumour development 6.

The disease primarily is a hamartomatous disorder that involves the ectoderm and mesoderm. Usually three types of neurofibromas occur in this disorder and are distinguished on the basis of their gross and microscopic appearances. 

  • localized neurofibroma (cutaneous neurofibroma) - the most common type, is a focal lesion that typically is located in the dermis and subcutis
  • diffuse neurofibroma (sub cutaneous neurofibroma) - localised in the subcutis, usually in the head and neck region. 
  • plexiform neurofibroma - considered pathognomonic if present ; they may be seen in virtually any location but usually occur in the neck, pelvis, and extremities 

Radiographic and clinical spectrum

Neurological (CNS)
Cutaneous
Skeletal
Chest
Vascular
Breast

Treatment and prognosis

No single treatment exists, and a combination of supportive and surgical therapies are employed depending on the specific tumours and anomalies present. 

Although prognosis is very variable, overall patients with neurofibromatosis type I have a life expectancy approximately half that of non affected individuals, usually succumbing to tumours or cardiovascular complications 8.  

See also

  • -<p><strong>Neurofibromatosis type 1 (NF1)</strong> or <strong>von Recklinghausen disease</strong> is a multisystem neurocutaneous disorder and the most common <a href="/articles/phakomatoses">phakomatosis </a><sup>1</sup>. Additionally it is also one of the most common inherited CNS disorders, autosomal dominant disorders and inherited tumour syndromes. </p><h4>Epidemiology</h4><p>Neurofibromatosis affects 1:<a href="tel:2500-3000">2500-3000</a> individuals <sup>3</sup>. In half of cases, the disease is inherited as an autosomal dominant condition. In the other 50% of cases the disease is due to a new mutation <sup>6</sup>. There is variable expression but 100% penetrance by 5 years of age <sup>6</sup>.</p><h4>Clinical presentation</h4><p>As is the case with many phakomatoses, NF1 results in a variety of abnormalities of variable severity. To make the clinical diagnosis you require two or more of following<sup>2</sup>:</p><ul>
  • +<p><strong>Neurofibromatosis type 1 (NF1)</strong> or <strong>von Recklinghausen disease</strong> is a multisystem neurocutaneous disorder and the most common <a href="/articles/phakomatoses">phakomatosis</a> <sup>1</sup>. Additionally it is also one of the most common inherited CNS disorders, autosomal dominant disorders and inherited tumour syndromes. </p><h4>Epidemiology</h4><p>Neurofibromatosis affects 1:<a href="tel:2500-3000">2500-3000</a> individuals <sup>3</sup>. In half of cases, the disease is inherited as an autosomal dominant condition. In the other 50% of cases the disease is due to a new mutation <sup>6</sup>. There is variable expression but 100% penetrance by 5 years of age <sup>6</sup>.</p><h4>Clinical presentation</h4><p>As is the case with many phakomatoses, NF1 results in a variety of abnormalities of variable severity. To make the clinical diagnosis you require two or more of following <sup>2</sup>:</p><ul>
  • -<li>overal risk of developing a MPNST is ~10%<sup>7</sup>
  • +<li>overal risk of developing a MPNST is ~10% <sup>7</sup>

ADVERTISEMENT: Supporters see fewer/no ads

Updating… Please wait.

 Unable to process the form. Check for errors and try again.

 Thank you for updating your details.